Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities

Since nivolumab significantly prolongs survival in patients with metastatic melanoma, the number of patients administered nivolumab is increasing, but only 30–40% of patients who received nivolumab monotherapy experienced objective tumor regression. Therefore, enhancing its anti-tumor immune respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Furudate, Sadanori, Fujimura, Taku, Kambayashi, Yumi, Hidaka, Takanori, Hashimoto, Akira, Aiba, Setsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118831/
https://www.ncbi.nlm.nih.gov/pubmed/27920696
http://dx.doi.org/10.1159/000450974
_version_ 1782469000976924672
author Furudate, Sadanori
Fujimura, Taku
Kambayashi, Yumi
Hidaka, Takanori
Hashimoto, Akira
Aiba, Setsuya
author_facet Furudate, Sadanori
Fujimura, Taku
Kambayashi, Yumi
Hidaka, Takanori
Hashimoto, Akira
Aiba, Setsuya
author_sort Furudate, Sadanori
collection PubMed
description Since nivolumab significantly prolongs survival in patients with metastatic melanoma, the number of patients administered nivolumab is increasing, but only 30–40% of patients who received nivolumab monotherapy experienced objective tumor regression. Therefore, enhancing its anti-tumor immune response is of great interest to dermato-oncologists. In this report, we present a case of multiple metastatic melanomas in the lung successfully treated with nivolumab (2 mg/kg every 3 weeks for 12 weeks) followed by ipilimumab (3 mg/kg every 3 weeks for 9 weeks), but with severe liver dysfunction.
format Online
Article
Text
id pubmed-5118831
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-51188312016-12-05 Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities Furudate, Sadanori Fujimura, Taku Kambayashi, Yumi Hidaka, Takanori Hashimoto, Akira Aiba, Setsuya Case Rep Oncol Case Report Since nivolumab significantly prolongs survival in patients with metastatic melanoma, the number of patients administered nivolumab is increasing, but only 30–40% of patients who received nivolumab monotherapy experienced objective tumor regression. Therefore, enhancing its anti-tumor immune response is of great interest to dermato-oncologists. In this report, we present a case of multiple metastatic melanomas in the lung successfully treated with nivolumab (2 mg/kg every 3 weeks for 12 weeks) followed by ipilimumab (3 mg/kg every 3 weeks for 9 weeks), but with severe liver dysfunction. S. Karger AG 2016-10-17 /pmc/articles/PMC5118831/ /pubmed/27920696 http://dx.doi.org/10.1159/000450974 Text en Copyright © 2016 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Furudate, Sadanori
Fujimura, Taku
Kambayashi, Yumi
Hidaka, Takanori
Hashimoto, Akira
Aiba, Setsuya
Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
title Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
title_full Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
title_fullStr Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
title_full_unstemmed Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
title_short Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
title_sort sequential therapy with nivolumab followed by ipilimumab induces complete response in metastatic melanoma of the lung but with severe hepatotoxicities
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118831/
https://www.ncbi.nlm.nih.gov/pubmed/27920696
http://dx.doi.org/10.1159/000450974
work_keys_str_mv AT furudatesadanori sequentialtherapywithnivolumabfollowedbyipilimumabinducescompleteresponseinmetastaticmelanomaofthelungbutwithseverehepatotoxicities
AT fujimurataku sequentialtherapywithnivolumabfollowedbyipilimumabinducescompleteresponseinmetastaticmelanomaofthelungbutwithseverehepatotoxicities
AT kambayashiyumi sequentialtherapywithnivolumabfollowedbyipilimumabinducescompleteresponseinmetastaticmelanomaofthelungbutwithseverehepatotoxicities
AT hidakatakanori sequentialtherapywithnivolumabfollowedbyipilimumabinducescompleteresponseinmetastaticmelanomaofthelungbutwithseverehepatotoxicities
AT hashimotoakira sequentialtherapywithnivolumabfollowedbyipilimumabinducescompleteresponseinmetastaticmelanomaofthelungbutwithseverehepatotoxicities
AT aibasetsuya sequentialtherapywithnivolumabfollowedbyipilimumabinducescompleteresponseinmetastaticmelanomaofthelungbutwithseverehepatotoxicities

Ejemplares similares